Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The efficacy of biologics for the treatment of Crohn’s disease (CD) is affected by the drug concentrations. We aimed to evaluate the importance of albumin and globulin which are known to be associated with drug concentrations as prognostic biomarkers in CD. Methods: In total, 121 pediatric patients with CD who had received anti-tumor necrosis factor (TNF)-α therapy were retrospectively examined between January 2010 and February 2019. Results: Relapse was observed in 48.8% of patients (59/121). The level of calprotectin (odds ratio, 2.13; p=0.03) and the albumin-to-globulin ratio (AGR) at 1 year after anti-TNF-α therapy (odds ratio, 0.0002; p=0.003) were associated with relapse. The AGR at 1 year after anti-TNF-α therapy was the only factor associated with the time-to-relapse (hazard ratio, 0.02; p<0.001). The optimal AGR cutoff value for the prediction of relapse was 1.47 (area under the curve, 0.916; p<0.001). The median infliximab trough level (TL) was lower in patients with AGRs <1.47 than in those with AGRs ≥1.47. Anti-drug antibody (ADA) concentrations were negatively correlated with the AGR at 1 year of anti-TNF-α therapy (r=–0.413, p=0.032). Conclusions: AGR can be used to predict relapse. Patients with AGRs <1.47 at 1 year after anti-TNF-α therapy are more likely to have low drug TLs and develop ADAs, which increase the possibility of relapse than those with AGRs ≥1.47. Therefore, if the AGR at 1 year after anti-TNF-α therapy is less than 1.47, clinicians should monitor disease activity, assess the TLs of the anti- TNF-α agents, test for ADAs and determine the appropriate therapeutic strategies.
Abstract
Background/Aims: The efficacy of biologics for the treatment of Crohn’s disease (CD) is affected by the drug concentrations. We aimed to evaluate the importance of albumin and globulin which are known to be associated with drug concentrations as prognostic biomarkers in CD. Methods: In total, 121 pediatric patients with CD who had received anti-tumor necrosis factor (TNF)-α therapy were retrospectively examined between January 2010 and February 2019. Results: Relapse was observed in 48.8% of patients (59/121). The level of calprotectin (odds ratio, 2.13; p=0.03) and the albumin-to-globulin ratio (AGR) at 1 year after anti-TNF-α therapy (odds ratio, 0.0002; p=0.003) were associated with relapse. The AGR at 1 year after anti-TNF-α therapy was the only factor associated with the time-to-relapse (hazard ratio, 0.02; p<0.001). The optimal AGR cutoff value for the prediction of relapse was 1.47 (area under the curve, 0.916; p<0.001). The median infliximab trough level (TL) was lower in patients with AGRs <1.47 than in those with AGRs ≥1.47. Anti-drug antibody (ADA) concentrations were negatively correlated with the AGR at 1 year of anti-TNF-α therapy (r=–0.413, p=0.032). Conclusions: AGR can be used to predict relapse. Patients with AGRs <1.47 at 1 year after anti-TNF-α therapy are more likely to have low drug TLs and develop ADAs, which increase the possibility of relapse than those with AGRs ≥1.47. Therefore, if the AGR at 1 year after anti-TNF-α therapy is less than 1.47, clinicians should monitor disease activity, assess the TLs of the anti- TNF-α agents, test for ADAs and determine the appropriate therapeutic strategies.
참고문헌 (46)
- Baumgart DC, "Inflammatory bowel disease : clinical aspects and established and evolving therapies", Lancet, 369, pp.1641~1657 (2007)
- Hyams JS, "Inflammatory bowel disease", Pediatr Rev, 26, pp.314~320 (2005)
- Rosen MJ, "Inflammatory bowel disease in children and adolescents", JAMA Pediatr, 169, pp.1053~1060 (2015)
- Cuffari C, "Inflammatory bowel disease in children : a pediatrician’s perspective", Minerva Pediatr, 58, pp.139~157 (2006)
- Cuffari C, "Inflammatory bowel disease in the pediatric and adolescent patient", Gastroenterol Clin North Am, 31, pp.275~291 (2002)
- Sahmoud T, "Identifying patients with a high risk of relapse in quiescent Crohn’s disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives", Gut, 37, pp.811~818 (1995)
- Liverani E, "How to predict clinical relapse in inflammatory bowel disease patients", World J Gastroenterol, 22, pp.1017~1033 (2016)
- Yarur AJ, "Predictors of aggressive inflammatory bowel disease", Gastroenterol Hepatol(N Y), 7, pp.652~659 (2011)
- Chauhan N, "Clinical variables as predictors of first relapse in pediatric Crohn’s disease", Cureus, 11, pp.e4980~ (2019)
- Hojsak I, "Risk factors for relapse and surgery rate in children with Crohn’s disease", Eur J Pediatr, 173, pp.617~621 (2014)
- Ziv-Baran T, "Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease", Aliment Pharmacol Ther, 48, pp.1242~1250 (2018)
- Scaldaferri F, "Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab", PLoS One, 12, pp.e0186575~ (2017)
- Hemperly A, "Clinical pharmacology in adult and pediatric inflammatory bowel disease", Inflamm Bowel Dis, 24, pp.2527~2542 (2018)
- Garcês S, "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases : a systematic review of the literature with a metaanalysis", Ann Rheum Dis, 72, pp.1947~1955 (2013)
- Rosen MJ, "Review article : applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis", Aliment Pharmacol Ther, 41, pp.1094~1103 (2015)
- 최소윤, "Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease", Gut and Liver, 13(5), pp.541~548 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Hiroshi Nakase, "Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease", Gut and Liver, 14(1), pp.7~19 (2020), 거트앤리버 소화기연관학회협의회
- Levitt DG, "Human serum albumin homeostasis : a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements", Int J Gen Med, 9, pp.229~255 (2016)
- Schoenefuss F, "Serum γ-globulin and albumin concentrations predict secondary loss of response to anti-TNFα in inflammatory bowel disease patients", Eur J Gastroenterol Hepatol, 31, pp.1563~1568 (2019)
- Levine A, "ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents", J Pediatr Gastroenterol Nutr, 58, pp.795~806 (2014)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Foster AJ, "Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients", World J Gastroenterol, 25, pp.1266~1277 (2019)
- Zubin G, "Predicting endoscopic Crohn’s disease activity before and after induction therapy in children : a comprehensive assessment of PCDAI, CRP, and fecal calprotectin", Inflamm Bowel Dis, 21, pp.1386~1391 (2015)
- Tibble JA, "Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease", Gastroenterology, 119, pp.15~22 (2000)
- Diederen K, "Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission", Aliment Pharmacol Ther, 45, pp.951~960 (2017)
- Qin G, "Serum albumin and C-reactive protein", albumin ratio are useful biomarkers of Crohn’s disease activity, 2016, pp.22, 4393~4400
- André C, "C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn’s disease", Scott Med J, 28, pp.26~29 (1983)
- Brignola C, "A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease", Gastroenterology, 91, pp.1490~1494 (1986)
- Don BR, "Serum albumin : relationship to inflammation and nutrition", Semin Dial, 17, pp.432~437 (2004)
- Taverna M, "Specific antioxidant properties of human serum albumin", Ann Intensive Care, 3, pp.4~ (2013)
- Nisar PJ, "Preoperative hypoalbuminemia is associated with adverse outcomes after ileoanal pouch surgery", Inflamm Bowel Dis, 18, pp.1034~1041 (2012)
- Najarian RM, "Microscopic", "backwash"ileitis and its association with Colonic disease in new onset pediatric ulcerative colitis, 2019, pp.68, 835~840
- Huang W, "Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn’s disease : a meta-analysis of observational studies", J Crohns Colitis, 9, pp.293~301 (2015)
- Tomasi TB Jr, "Human gamma globulin", Blood, 25, pp.382~403 (1965)
- Moses J, "Time to antibody detection and associated factors for presence of antidrug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy", Eur J Gastroenterol Hepatol, 31, pp.1228~1233 (2019)
- Vermeire S, "Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease", Gut, 56, pp.1226~1231 (2007)
- Su CG, "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease", Gastroenterology, 125, pp.1544~1546 (2003)
- Niedziela JT, "Albumin-to-globulin ratio as an independent predictor of mortality in chronic heart failure", Biomark Med, 12, pp.749~757 (2018)
- Zhou T, "Pretreatment albumin globulin ratio has a superior prognostic value in laryngeal squamous cell carcinoma patients : a comparison study", J Cancer, 10, pp.594~601 (2019)
- Yue W, "The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma", Clin Chim Acta, 485, pp.316~322 (2018)
- Lv GY, "Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers : a meta-analysis", Clin Chim Acta, 476, pp.81~91 (2018)
- Du XJ, "The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma", PLoS One, 9, pp.e94473~ (2014)
- Liu Z, "The prognostic value of preoperative serum albumin-globulin ratio for high-grade bladder urothelial carcinoma treated with radical cystectomy : a propensity score-matched analysis", J Cancer Res Ther, 13, pp.837~843 (2017)
- Li J, "Prognostic value of pretreatment albumin to globulin ratio in lung cancer : a metaanalysis", Nutr Cancer, 73, pp.75~82 (2021)
- Dipasquale V, "Pouchitis in pediatric ulcerative colitis : a multicenter study on behalf of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition", Dig Liver Dis, 51, pp.1551~1556 (2019)
- Diakos CI, "Cancerrelated inflammation and treatment effectiveness", Lancet Oncol, 15, pp.e493~e503 (2014)